Missouri residents who have exhausted conventional disease cures will have access to experimental drugs under legislation signed on Monday by Gov. Jay Nixon.
The so-called Right to Try legislation gives patients and their doctors the ability to procure drugs that have yet to gain approval from the U.S. Food and Drug Administration if the pharmaceutical manufacturer agrees to provide the product.
If you were dying and had exhausted all conventional treatment options, wouldn’t you want immediate access to a drug that might prove to be a miracle cure?
That’s the promise of legislation that, if signed by Gov. Jay Nixon, would make Missouri the third state in the country - after Colorado and Louisiana – to enact a so-called “Right to Try” law, which aims to get investigational drugs into the hands of terminally ill patients as quickly as possible.
Regulators released a broad plan Wednesday, designed to prevent meat producers from using drugs that are also used to treat sick humans. That means some changes Midwest farmers and ranchers will have to get used to.
The Food and Drug Administration is ratcheting up inspections this year on cantaloupe farms and other processing facilities throughout the country. The increased scrutiny is in direct response to two large-scale outbreaks of deadly food borne bacteria.
Both outbreaks were tied directly to tainted cantaloupe. Salmonella on melons from Indiana and listeria on some from Colorado killed 36 people.
The repercussions were felt by cantaloupe growers throughout the country - including Michael Hirakata in Colorado’s Arkansas River valley.
Originally published on Tue April 3, 2012 10:05 pm
A nonprofit foundation set up to support scientific research of interest to the Food and Drug Administration is finally starting to take off after years of struggling financially — and it's about to get some long-promised funding from the FDA.
But some critics worry that this foundation, which will also raise money from private sources including industry, could provide a way for the food and medical industries to sway FDA decisions.